ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
6,084.19
0.82%
Dow Jones
44,148.56
0.00%
US Dollar vs MXN
20.14648
0.08%
Brent Oil
73.255
-0.26%
Bitcoin
100,943.58
-0.25%
Pepperstone
Advertisement
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Generation Bio Company (GBIO)

  7. Generation Bio Company (GBIO) Noticias

Generation Bio Company

Generation Bio Company (GBIO)

NASDAQ
1.27
-0.01
(-0.78%)
Cerrado 11 Diciembre 3:00PM
Delayed by 15 minutes
1.27
0.00
( 0.00% )
Pre Mercado: 6:00AM
Delayed by 15 minutes

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Premium

GBIO Noticias

Solo noticias oficiales

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Edgar (US Regulatory)
06 Noviembre 2024
GBIO (-0.78%)

Form 8-K - Current report
Edgar (US Regulatory)
06 Noviembre 2024
GBIO (-0.78%)

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Edgar (US Regulatory)
23 Octubre 2024
GBIO (-0.78%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
17 Octubre 2024
GBIO (-0.78%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
17 Octubre 2024
GBIO (-0.78%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
17 Octubre 2024
GBIO (-0.78%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
17 Octubre 2024
GBIO (-0.78%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
17 Octubre 2024
GBIO (-0.78%)

Form EFFECT - Notice of Effectiveness
Edgar (US Regulatory)
15 Agosto 2024
GBIO (-0.78%)

Form S-3 - Registration statement under Securities Act of 1933
Edgar (US Regulatory)
07 Agosto 2024
GBIO (-0.78%)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Edgar (US Regulatory)
07 Agosto 2024
GBIO (-0.78%)

Form 8-K - Current report
Edgar (US Regulatory)
07 Agosto 2024
GBIO (-0.78%)

GBIO Discussion

Ver más
PonkenPlonken PonkenPlonken 1 mes hace
If things arent all too dire at MRNA, double down on GBIO should be coming soon
👍️0
Monksdream Monksdream 3 meses hace
GBIO under $3
👍️0
Monksdream Monksdream 5 meses hace
GBIO under $3
👍️0
glenn1919 glenn1919 9 meses hace
GBIO...................................https://stockcharts.com/h-sc/ui?s=GBIO&p=W&b=5&g=0&id=p86431144783
👍️0
willlbone willlbone 1 año hace
Welcome to Oct 2023. Buy the dip
👍️0
crudeoil24 crudeoil24 5 años hace
Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, today announced the pricing of its initial public offering of 10,526,316 shares of its common stock at an initial public offering price of $19.00 per share. In addition, Generation Bio has granted the underwriters a 30-day option to purchase up to 1,578,947 additional shares of common stock at the initial public offering price, less the underwriting discount and commissions. All of the shares are being offered by Generation Bio.
Generation Bio has been approved for listing on the Nasdaq Global Select Market and is expected to begin trading on Friday, June 12, 2020 under the ticker symbol “GBIO.” The gross proceeds of the offering, before deducting the underwriting discount and commissions and other offering expenses payable by Generation Bio, are expected to be approximately $200 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on Tuesday, June 16, 2020, subject to customary closing conditions.
👍️0
crudeoil24 crudeoil24 5 años hace
Generation Bio Co. is a genetic medicines company. The Company is developing a class of gene therapy utilizing its non-viral gene therapy platform to provide durable, redosable treatments for patients living with rare and prevalent diseases. The Company’s non-viral gene therapy platform includes its DNA construct called closed-ended DNA (ceDNA), its cell-targeted lipid nanoparticle delivery system (ctLNP) and its established, scalable capsid-free manufacturing process. The Company is developing gene therapies to provide targeted delivery of genetic payloads that include multiple genes to a range of tissues of diseases. The Company is also engineering its gene therapies to be redosable, which enable patient titration to reach the desired therapeutic expression and to maintain efficiency in a patient’s life. The Company is a preclinical stage company and have not identified a product candidate.
👍️0

Su Consulta Reciente

NASDAQ
GBIO
Generation Bio
BIT
1EOAN
E. On
NASDAQ
GNTAD
NYSE
AVB
Avalonbay Communities
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados